Bioxytran, Inc., a clinical-stage biotechnology company, has announced a research collaboration with the University of Georgia (UGA) to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu. The collaboration is part of a $100 million grant aimed at evaluating Bioxytran’s novel galectin antagonist as a potential […]















